Characteristics of 126 patients treated with second-generation TKI
| Characteristic . | Median or no. . | Range or percentage . |
|---|---|---|
| Demographics (n = 126) | ||
| Age, y | 56 | 15-79 |
| Female sex | 59 | 46 |
| Treatment before second-generation TKI | ||
| Number of treatments | 2 | 1-7 |
| Only imatinib ± HU ± anagrelide | 31 | 25 |
| Interferon | 63 | 50 |
| Chemotherapy | 56 | 44 |
| Homoharringtonine | 12 | 9 |
| Other investigational treatments | 19 | 15 |
| Bone marrow transplantation ± DLI ± XRT | 13 | 10 |
| Another second-generation TKI | 3 | 2 |
| Imatinib therapy | ||
| Time on imatinib | 29 | 2-78 |
| Response to imatinib | ||
| MCyR | 44 | 35 |
| CCyR | 30 | 24 |
| No CyR | 57 | 45 |
| NA | 25 | 20 |
| Characteristic . | Median or no. . | Range or percentage . |
|---|---|---|
| Demographics (n = 126) | ||
| Age, y | 56 | 15-79 |
| Female sex | 59 | 46 |
| Treatment before second-generation TKI | ||
| Number of treatments | 2 | 1-7 |
| Only imatinib ± HU ± anagrelide | 31 | 25 |
| Interferon | 63 | 50 |
| Chemotherapy | 56 | 44 |
| Homoharringtonine | 12 | 9 |
| Other investigational treatments | 19 | 15 |
| Bone marrow transplantation ± DLI ± XRT | 13 | 10 |
| Another second-generation TKI | 3 | 2 |
| Imatinib therapy | ||
| Time on imatinib | 29 | 2-78 |
| Response to imatinib | ||
| MCyR | 44 | 35 |
| CCyR | 30 | 24 |
| No CyR | 57 | 45 |
| NA | 25 | 20 |
TKI indicates tyrosine kinase inhibitor; HU, hydroxyurea; DLI, donor lymphocyte infusions; XRT, radiotherapy; CyR, cytogenetic response; and NA, not available.